---
title: "Bruce C. Cozadd，爵士制药的董事长兼首席执行官，报告了出售普通股的情况"
description: "爵士制药 plc 的董事长兼首席执行官 Bruce C. Cozadd 报告了公司普通股的处置。完整的文件可通过提供的链接获取。此消息由公共技术公司生成，仅供信息参考，不应被视为财务、投资或法律建议"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/238803917.md"
published_at: "2025-05-05T23:01:14.000Z"
---

# Bruce C. Cozadd，爵士制药的董事长兼首席执行官，报告了出售普通股的情况

> 爵士制药 plc 的董事长兼首席执行官 Bruce C. Cozadd 报告了公司普通股的处置。完整的文件可通过提供的链接获取。此消息由公共技术公司生成，仅供信息参考，不应被视为财务、投资或法律建议

爵士制药公司（Jazz Pharmaceuticals plc）的董事长兼首席执行官布鲁斯·C·科扎德（Bruce C. Cozadd）报告了该公司普通股的处置。完整的文件可以通过以下链接访问。免责声明：本新闻简报由公共技术公司（Public Technologies，PUBT）使用生成性人工智能创建。尽管 PUBT 努力提供准确和及时的信息，但此 AI 生成的内容仅供参考，不应被解读为财务、投资或法律建议。爵士制药公司通过美国证券交易委员会（U.S. Securities and Exchange Commission）运营的电子数据收集、分析和检索系统（EDGAR）于 2025 年 5 月 5 日发布了用于生成本新闻简报的原始内容（参考 ID：0001765581-25-000039），并对此信息的内容承担全部责任。© 版权 2025 - 公共技术公司（PUBT）原始文件：这里

### Related Stocks

- [JAZZ.US - 爵士制药](https://longbridge.com/zh-CN/quote/JAZZ.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| A Look At Jazz Pharmaceuticals (JAZZ) Valuation After Positive Ziihera Phase 3 Gastroesophageal Cancer Results | Jazz Pharmaceuticals (JAZZ) has gained attention following positive Phase 3 results for its HER2-targeted drug Ziihera i | [Link](https://longbridge.com/zh-CN/news/271933572.md) |
| What Analysts Are Saying About Jazz Pharmaceuticals Stock | Analysts have provided mixed ratings for Jazz Pharmaceuticals (NASDAQ:JAZZ) over the past three months, with 11 analysts | [Link](https://longbridge.com/zh-CN/news/272265895.md) |
| Jazz Pharmaceuticals Showcases Rare Disease Breakthroughs and Growth Strategy in New Presentation | Jazz Pharmaceuticals plc presented at the 44th Annual J.P. Morgan Healthcare Conference, showcasing its achievements and | [Link](https://longbridge.com/zh-CN/news/272449426.md) |
| Jazz Pharmaceuticals Completes Acquisition of Chimerix | Jazz Pharmaceuticals has acquired Chimerix, integrating it into its corporate strategy. The acquisition includes the Pha | [Link](https://longbridge.com/zh-CN/news/272282470.md) |
| Jazz Pharmaceuticals Announce Positive Efficacy From Ziihera Phase 3 Trial | Jazz Pharmaceuticals PLC :ZIIHERA® (ZANIDATAMAB-HRII) COMBINATIONS ACHIEVE UNPRECEDENTED RESULTS IN FIRST-LINE HER2+ LOC | [Link](https://longbridge.com/zh-CN/news/271691426.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。
